Startups
Startups
Private companies covered in BlitzLab funding research. Each profile aggregates the company's funding history, Blitz findings, and sources, and is updated when a new funding article publishes. Research only — not investment advice.
- Opentrons — Opentrons builds open, API-driven lab robots and software that standardize and automate scientific experiments. · Series E · $40M · Oct 2026
- Serval — Serval builds Catalyst, an automation agent embedded in an enterprise service management platform that lets non-engineers build and run code-based workflows. · Series C · $150M · Oct 2026
- Plato — Plato builds simulated workplaces where AI models can learn real jobs and be evaluated on whether they do the work correctly. · Series A · $16M · Oct 2026
- Numeracle — Numeracle provides Entity Identity Management, verifying that a business is a real, legitimate, operating entity so its calls are trusted. · Growth investment · $28M · Oct 2026
- Broccoli — Broccoli is an AI platform for home-services businesses, whose agents answer calls, book appointments, follow up on estimates, and handle other office work for the trades. · Series A and Series B (combined) · $52M · Oct 2026
- Casap — Casap is an AI agent platform for financial services that works the full dispute lifecycle for financial institutions. · Series B · $56M · Oct 2026
- Upwind — Upwind provides a runtime-based cloud and AI security platform for cloud workloads, APIs, and AI agents. · Series C · $400M · Oct 2026
- Fragment — Fragment builds AI agents that automate the purchasing and payment exceptions enterprise software leaves behind, starting with direct procurement. · Series A + Seed (launch total) · $56M · Oct 2026
- Foundry Robotics — Foundry Robotics builds and operates autonomous factories for complex assembly, offering manufacturing-as-a-service through AI robot cells and its FoundryOS platform. · Series A · $100M · Oct 2026
- Biosphere — Biosphere is developing a flexible industrial biomanufacturing platform to produce critical chemicals domestically at scale. · Contract (U.S. Department of War, via the Defense Industrial Base Consortium) · $21M · Oct 2026
- EdgeCore — EdgeCore Digital Infrastructure is a wholesale data center developer, owner, and operator. · Asset-backed securitization (ABS) · $521M · Oct 2026
- Hyperbolic — Hyperbolic builds Forge, a unified control plane that standardizes heterogeneous GPU clusters, and plans a Global Compute Grid marketplace for GPU capacity. · Series A1 · $30M · Oct 2026
- Emvolon — Emvolon builds modular chemical systems that convert waste methane into biomethanol directly at the waste site. · Series A · $22M · Oct 2026
- Vera Health — Vera Health is a clinical AI search platform that answers clinicians' questions from medical literature and guidelines, grading the strength of the evidence first. · Series A · $28.5M · Oct 2026
- Avante — Avante is an enterprise AI platform for benefits teams, whose AI agents do benefits teams' recurring work and give employees personalized guidance on their plans. · Series A · $30M · Oct 2026
- Infisical — Infisical is a security infrastructure company that helps organizations manage secrets, certificates, encryption keys, and privileged access, and secures AI agents' access to company systems. · Series B · $40M · Oct 2026
- Hyphenate — Hyphenate provides self-learning AI finance agents for the office of the CFO, covering order-to-cash, treasury, accounting, procure-to-pay, and reporting. · Series A · $45M · Oct 2026
- General Compute — General Compute is building an inference neocloud that finances, deploys, and operates specialized chips inside rented colocation space. · Series A · $100M · Oct 2026
- Nevis — Nevis provides an AI operating system for wealth management, in which AI agents complete advisers' operational work end to end. · Series B · $70M · Oct 2026
- Formic — Formic offers Robot-as-a-Service, deploying, servicing, financing, and maintaining robots in customers' factories for a recurring monthly payment with no upfront capital investment. · Growth round (including Series B) · $50M · Oct 2026
- KymaThera — KymaThera develops precision medicines for genetically defined diseases, led by K-1728, an oral pan-mutant selective PI3Kα inhibitor. · Series B · $80M · Oct 2026
Research only — not investment advice. Private-company figures are company-reported or press-reported, not audited. BlitzLab scores blitzscaling strategy from public data.